302 related articles for article (PubMed ID: 20228675)
1. Cinacalcet for the treatment of primary hyperparathyroidism.
Dillon ML; Frazee LA
Am J Ther; 2011 Jul; 18(4):313-22. PubMed ID: 20228675
[TBL] [Abstract][Full Text] [Related]
2. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.
Khan A; Grey A; Shoback D
J Clin Endocrinol Metab; 2009 Feb; 94(2):373-81. PubMed ID: 19193912
[TBL] [Abstract][Full Text] [Related]
3. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A
Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106
[TBL] [Abstract][Full Text] [Related]
4. Management of skeletal health in patients with asymptomatic primary hyperparathyroidism.
Lewiecki EM
J Clin Densitom; 2010; 13(4):324-34. PubMed ID: 21029971
[TBL] [Abstract][Full Text] [Related]
5. Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.
Norman J; Lopez J; Politz D
Ann Surg Oncol; 2012 May; 19(5):1466-71. PubMed ID: 21922336
[TBL] [Abstract][Full Text] [Related]
6. Nonsurgical management of mild primary hyperparathyroidism - a reasonable option.
Grey A
Clin Endocrinol (Oxf); 2012 Nov; 77(5):639-44. PubMed ID: 22803518
[TBL] [Abstract][Full Text] [Related]
7. Calcimimetics versus parathyroidectomy for treatment of primary hyperparathyroidism: retrospective chart analysis of a prospective database.
Keutgen XM; Buitrago D; Filicori F; Kundel A; Elemento O; Fahey TJ; Zarnegar R
Ann Surg; 2012 May; 255(5):981-5. PubMed ID: 22470074
[TBL] [Abstract][Full Text] [Related]
8. Medical management of primary hyperparathyroidism.
Khan AA
J Clin Densitom; 2013; 16(1):60-3. PubMed ID: 23374743
[TBL] [Abstract][Full Text] [Related]
9. [Nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: focus on calciomimetics].
Brardi S; Ponchietti R; Duranti E
G Ital Nefrol; 2016; 33(6):. PubMed ID: 28134399
[TBL] [Abstract][Full Text] [Related]
10. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
de Francisco AL
Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.
Duntas LH; Stathatos N
Endocrine; 2011 Jun; 39(3):199-204. PubMed ID: 21442382
[TBL] [Abstract][Full Text] [Related]
12. [Medical treatment of primary hyperparathyroidism: role of calcimimetics].
Muñoz Torres M; García Martín A
Endocrinol Nutr; 2009 Apr; 56 Suppl 1():29-34. PubMed ID: 19627758
[TBL] [Abstract][Full Text] [Related]
13. Transient hypercortisolism and symptomatic hyperthyroidism associated to primary hyperparathyroidism in an elderly patient: case report and literature review.
Sabbadin C; Donà G; Bordin L; Iacobone M; Camozzi V; Mian C; Armanini D
BMC Endocr Disord; 2015 Jan; 15():4. PubMed ID: 25631825
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic challenges in elderly patients with symptomatic hypercalcaemia caused by primary hyperparathyroidism.
Jacobs L; Samson MM; Verhaar HJ; Koek HL
Neth J Med; 2012 Jan; 70(1):35-8. PubMed ID: 22271812
[TBL] [Abstract][Full Text] [Related]
16. Asymptomatic primary hyperparathyroidism: surgical and medical management.
Francucci CM; Ceccoli L; Caudarella R; Rilli S; Vescini F; Boscaro M
J Endocrinol Invest; 2011 Jul; 34(7 Suppl):50-4. PubMed ID: 21985981
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet hydrochloride for the treatment of hyperparathyroidism.
Verheyen N; Pilz S; Eller K; Kienreich K; Fahrleitner-Pammer A; Pieske B; Ritz E; Tomaschitz A
Expert Opin Pharmacother; 2013 Apr; 14(6):793-806. PubMed ID: 23452174
[TBL] [Abstract][Full Text] [Related]
18. Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.
Imanishi Y; Kawata T; Kenko T; Wada M; Nagano N; Miki T; Arnold A; Inaba M
Calcif Tissue Int; 2011 Jul; 89(1):29-35. PubMed ID: 21541686
[TBL] [Abstract][Full Text] [Related]
19. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity.
Peacock M; Bilezikian JP; Bolognese MA; Borofsky M; Scumpia S; Sterling LR; Cheng S; Shoback D
J Clin Endocrinol Metab; 2011 Jan; 96(1):E9-18. PubMed ID: 20943783
[TBL] [Abstract][Full Text] [Related]
20. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.
Filopanti M; Verga U; Ermetici F; Olgiati L; Eller-Vainicher C; Corbetta S; Persani L; Beck-Peccoz P; Spada A
Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]